President Biden, Vice President Harris, and Democrats in Congress have taken historic action to lower health care costs and save Americans thousands of dollars a year.
Through the Inflation Reduction Act, the Biden-Harris administration and Democrats in Congress lowered health insurance costs for people buying coverage on their own. This year, a record 21.4 million people signed up for coverage under the ACA, with families saving an average of $2,400 per year on their health coverage. The Inflation Reduction Act also capped annual out-of-pocket drug costs for seniors, capped the cost of insulin at $35/month, provided free vaccines to seniors, and, for the first time in history, gave Medicare the power to negotiate lower drug prices. Bringing down the cost of health care gives families more breathing room and helps keep food on the table and a roof over heads for millions of people.
Meanwhile, the MAGA Republican Party, led by Donald Trump, is escalating their attacks on American health care and has doubled down on their plan to deny tens of millions of Americans affordable, lifesaving health care. Not a single Republican in Congress voted to pass the Inflation Reduction Act and they continue to work to repeal the law altogether. Project 2025, a dangerous blueprint for a Trump second term, fully repeals the Inflation Reduction Act’s prescription drug provisions that are saving Americans thousands of dollars on health care. At the same time, big drug companies are in court trying to ban Medicare from negotiating lower drug prices. If Trump and MAGA Republicans get their way, tens of millions of Americans will lose affordable life-saving health care and costs will go up for millions more.
By The Numbers:
1.5 million Americans on Medicare who use insulin are now saving on average $501 annually thanks to the $35 per month insulin cap and thousands of other Americans have seen their insulin prices fall thanks to Democratic investigations and policies holding pharmaceutical companies responsible for their price gouging.
9,046,000 Americans who take one or more of the first ten drugs selected by Medicare for negotiation will see lower prices starting in 2026. In 2026 alone, seniors will save $1.5 billion out-of-pocket and taxpayers will save $6 billion thanks to lower negotiated prices.
67.4 million Americans on Medicare are now protected from drug company price hikes on drugs provided through Medicare Part B. Drug companies that increase prices faster than inflation must pay a rebate to Medicare, which lowers out-of-pocket costs for seniors. Since this took effect in 2023, over 770,000 seniors nationwide have benefitted from penalties imposed on 98 drugs, saving nearly $3 billion for seniors and taxpayers.
10,269,000 of the United States’s seniors, 20 percent of the state’s Part D population, received the shingles vaccination and other recommended vaccinations free of cost last year
38,279,655 Americans will save an average $396.08 thanks to the Inflation Reduction Act’s $35 insulin cap, free vaccines, and $2,000 annual out-of-pocket cost cap that takes effect in 2025. In 2022, 38,279,655 Americans on Medicare but not on a low income subsidy spent an average of $462 out-of-pocket on prescription drugs.
19.7 million Americans are saving an average of $700 on monthly health insurance premiums.
80,855,947 Americans on Medicaid and CHIP will maintain or gain access to expanded vaccine coverage of which around 20.5 percent are Black, 36.9 percent are Hispanic, and 3.4 percent are Asian American or Pacific Islanders according to national averages.
The Details:
Medicare’s price negotiation power will lower drug costs for over 9 million Americans. Made possible by the Inflation Reduction Act, Medicare is now negotiating prices with drug companies for some of the most expensive and commonly prescribed drugs. Medicare announced new, lower negotiated prices for the first ten drugs selected for negotiation, with list prices lowered by up to 79 percent for seniors. Around 9,046,000 Americans are currently takingone or more of the ten drugs which were brought down in price, of which around 48 percent are women.
Below is a breakdown of the discounts negotiated by Medicare for the first 10 drugs selected for negotiation: